{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:30:25Z","timestamp":1783452625083,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010888","name":"Wuhan Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017958","name":"Health Commission of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112144","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:56:16Z","timestamp":1715316976000},"page":"112144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"134","author":[{"given":"Tianlin","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3894-341X","authenticated-orcid":false,"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.112144_b0005","unstructured":"w.b.e. Cancer Genome Atlas Research Network. Electronic address, N. Cancer Genome Atlas Research, Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma, Cell 169(7) (2017) 1327-1341 e23."},{"issue":"9","key":"10.1016\/j.intimp.2024.112144_b0010","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/liv.15251","article-title":"Changing epidemiology of hepatocellular carcinoma in Asia","volume":"42","author":"Zhang","year":"2022","journal-title":"Liver Int"},{"issue":"10","key":"10.1016\/j.intimp.2024.112144_b0015","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41575-022-00620-y","article-title":"Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0030","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s43018-022-00357-2","article-title":"Molecular pathogenesis and systemic therapies for hepatocellular carcinoma","volume":"3","author":"Llovet","year":"2022","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.intimp.2024.112144_b0040","doi-asserted-by":"crossref","unstructured":"T. de Castro, L.S. Jochheim, M. Bathon, S. Welland, B. Scheiner, K. Shmanko, D. Roessler, N. Ben Khaled, M. Jeschke, J.M. Ludwig, J.U. Marquardt, A. Weinmann, M. Pinter, C.M. Lange, A. Vogel, A. Saborowski, Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience, Ther Adv Med Oncol 14 (2022) 17588359221080298.","DOI":"10.1177\/17588359221080298"},{"issue":"16","key":"10.1016\/j.intimp.2024.112144_b0045","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","article-title":"Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0050","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.intimp.2024.112144_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.793343","article-title":"Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma","volume":"12","author":"Wu","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2024.112144_b0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jare.2021.01.018","article-title":"Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden","volume":"33","author":"Tang","year":"2021","journal-title":"J Adv Res"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0065","first-page":"208","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial, Lancet","volume":"7","author":"Kaseb","year":"2022","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.intimp.2024.112144_b0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2022.06.058","article-title":"Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials","volume":"174","author":"Fulgenzi","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.intimp.2024.112144_b0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev-med-042220-021121","article-title":"Hepatocellular Carcinoma Immunotherapy","volume":"73","author":"Sperandio","year":"2022","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.intimp.2024.112144_b0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/hbsn-22-469","article-title":"A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights","volume":"12","author":"Xie","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"8","key":"10.1016\/j.intimp.2024.112144_b0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-021-00438-0","article-title":"Advances in immunotherapy for hepatocellular carcinoma","volume":"18","author":"Sangro","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0090","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.intimp.2024.112144_b0095","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/gutjnl-2021-325288","article-title":"The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma","volume":"71","author":"Heinrich","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0100","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1038\/s41467-022-31312-5","article-title":"Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment","volume":"13","author":"Schneider","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.intimp.2024.112144_b0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.intimp.2024.112144_b0110","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1053\/j.gastro.2021.07.033","article-title":"Downstaging outcomes for hepatocellular carcinoma: results from the multicenter evaluation of reduction in tumor size before liver transplantation (MERITS-LT) consortium","volume":"161","author":"Mehta","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.29485","article-title":"Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis","volume":"67","author":"Kulik","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2024.112144_b0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.783236","article-title":"Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma","volume":"12","author":"Xing","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.intimp.2024.112144_b0130","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1093\/oncolo\/oyac183","article-title":"Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following non-sorafenib systemic therapy: an expansion cohort of REACH-2","volume":"27","author":"Finn","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.intimp.2024.112144_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101679","article-title":"Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): a randomised, multicentre, double-blind study","volume":"54","author":"Shao","year":"2022","journal-title":"EClinicalMedicine"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0140","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1159\/000506946","article-title":"Efficacy and safety of ramucirumab in asian and non-asian patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: pooled individual data analysis of two randomized studies","volume":"9","author":"Yen","year":"2020","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0145","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbac291","article-title":"Immune infiltration and clinical significance analyses of the coagulation-related genes in hepatocellular carcinoma","volume":"23","author":"He","year":"2022","journal-title":"Brief Bioinform"},{"issue":"5","key":"10.1016\/j.intimp.2024.112144_b0150","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/hep.31792","article-title":"Cancer-associated fibroblast-mediated cellular crosstalk supports hepatocellular carcinoma progression","volume":"73","author":"Song","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0155","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1038\/s41467-022-32283-3","article-title":"A single-cell atlas of the multicellular ecosystem of primary and metastatic hepatocellular carcinoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.intimp.2024.112144_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"Marinelli","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0165","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0170","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.32585","article-title":"Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation","volume":"77","author":"Zeng","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0175","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000521665","article-title":"surgery versus radiofrequency ablation for small hepatocellular carcinoma: a randomized controlled trial (SURF Trial)","volume":"11","author":"Takayama","year":"2022","journal-title":"Liver Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.112144_b0180","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","article-title":"Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma","volume":"70","author":"Leuchte","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.intimp.2024.112144_b0185","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/02656736.2022.2032406","article-title":"Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6","volume":"39","author":"Huang","year":"2022","journal-title":"Int J Hyperthermia"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030846","article-title":"Effectiveness of repeated stereotactic body radiation therapy for hepatocellular carcinoma-consideration of the locations of target lesions","volume":"15","author":"Yano","year":"2023","journal-title":"Cancers (basel)"},{"issue":"3","key":"10.1016\/j.intimp.2024.112144_b0195","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial","volume":"74","author":"Kim","year":"2021","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.intimp.2024.112144_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112798","article-title":"Emerging therapies for hepatocellular carcinoma (HCC)","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Cancers (basel)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:02:25Z","timestamp":1735308145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924006623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":40,"alternative-id":["S1567576924006623"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112144","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A study on combination of non-ablative local RFA with PD-1 and angiogenesis blocking to prolong survival through improvement of immune microenvironment in advanced Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112144"}}